26 results on '"BAX 855"'
Search Results
2. A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A
3. ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD) (AHEAD)
4. A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.
5. A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
6. Post Marketing Surveillance Study for ADYNOVATE in South Korea
7. POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
8. ADYNOVATE Drug Use-Results Survey
9. Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A
10. Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®
11. BAX 855 PK-guided Dosing (PROPEL)
12. Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures
13. Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)
14. BAX 855 Pediatric Study
15. BAX 855 Continuation
16. BAX 855 Dose-Escalation Safety Study
17. Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)
18. Successful Hemostasis with Extended Half-life Recombinant Factor VIII in Circumcision
19. Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial.
20. Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates.
21. Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients
22. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup
23. The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule.
24. Successful Hemostasis with Extended Half-life Recombinant Factor VIII in Circumcision.
25. Successful Hemostasis with Extended Half-life Recombinant Factor VIII in Circumcision
26. Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.